Hold Rating on Agilon: Margin Improvement Efforts Tempered by Persistent Profitability and Cost Pressures

In a report released today, Ryan Langston from TD Cowen maintained a Hold rating on Agilon Health, with a price target of $0.60.

Ryan Langston has given his Hold rating due to a combination of factors, including weaker-than-expected recent results and only gradual progress toward profitability. The company’s latest quarter showed a larger adjusted EBITDA loss than forecast, and management anticipates a meaningful decline in total membership next year, even as they target roughly breakeven EBITDA in 2026.

At the same time, Langston recognizes that Agilon is taking steps to improve margins through better Medicare Advantage pricing, more favorable payer contracts, and reduced Part D exposure, supported by a liquidity runway that appears adequate through the transition. However, he remains wary of ongoing medical cost inflation, potential adverse prior-year development, and lower profitability from ACO REACH lives, which together justify a sharply reduced price target and a neutral, rather than more optimistic, stance.

According to TipRanks, Langston is an analyst with an average return of -5.7% and a 39.82% success rate. Langston covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Centene, and HCA Healthcare.